UPCC 18121: A Phase II Study of NirAparib Dostarlimab and Radiotherapy in Metastatic PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR)

Age
99 years or below
Gender
All
Location
1

Brief description of study

Please refer to Section 4 of the full protocol (Objectives) Please refer to Section 18.4 of the full protocol (Analysis of Primary Endpoints) Please refer to Section 18.5 of the full protocol (Analysis of Secondary and Exploratory Endpoints)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 850234
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research